Mary and Bill Battle Professor of Multiple Myeloma. Immunotherapy , cellular therapy, clinical trials. I unapologetically believe MM can be CURED.
Nov 15, 2023 • 10 tweets • 3 min read
#ASH23 #myeloma Abstracts I find most clinically relevant, no particular order @mtmdphd 1/x
Dara-Vd in t(11;14) RRMM @NBahlis Very impressive efficacy. Kudos for reporting MRD by ITT in a single arm trial. 2/x ash.confex.com/ash/2023/webpr…
Oct 1, 2023 • 7 tweets • 2 min read
@Rfonsi1 , brilliant and-depth analysis as always 🙏🏼🙏🏼. I would also highlight CANOVA is a textbook example of informative censoring and its dangers. Censoring should be small, balanced between the arms and not "informed" by trial design. Let's see what happens here 1/X
Large number of censoring in the Pd arm. These are folks that are not dropping off for progression or toxicity, but for other reasons such as MD or patient choice. Consequences? It eats away power (fewer patients left) and arms can no longer be assumed similar 2/X
Sep 28, 2023 • 16 tweets • 3 min read
MASTER trial final results out in @TheLancetHaem Thanks @bdermanmd for the very nice commentary! Of course I find the results COOL! But I find the story behind it is just as nice! 1/X sciencedirect.com/science/articl…
c2015, moAbs cooking, MRD by NGS gaining steam, I had time, and had very supportive friends/collaborators @Phari @nsc_natalie @myeloma_doc_com @Chhabra_mayo @ravivij . Let's try something bold? Very naive, in retrospect. Glad my friends didn't mind 2/X
